Skip to main content
OpenTrials
Completed

NCT Number: NCT05650944

How Important Are Hematological Parameters in the Prognosis of Severe Covid-19 Patients?

It is aimed to reveal the treatment and prognostic values by evaluating the differences in hematological parameters and indices, especially in dead Covid-19 cases.

Material Method: It is planned to retrospectively examine the hemogram parameters of 125 male, 44 female and 169 critical Covid-19 patients hospitalized between 01.03.2020 and 31.12.2021. Subjects were divided into 2 groups as deceased (77) and living (92) patients according to demographic data such as age and gender.

Statistical evaluation: All analyzes were SPSS 25.0, Kolmogorov Smirnov test was used to determine distribution, median and interquartile range (Tukey's Hinges Percentile) were used to summarize variables. The differences between the Independent-Samples Mann Whitney U Test and the data of the patient groups and the optimal cut-off values, sensitivity and specificity values will be determined by ROC analysis. It will be considered statistically significant when the p value is below 0.05 (with the two-tailed test)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hisar Hospital Intercontinental

Istanbul, Turkey (Türkiye)

About this study

The aim of this study is to examine the effectiveness of routine laboratory complete blood count parameters and rates as diagnostic and prognostic criteria in severe COVID-19.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over the age of 18
  • Critical patients taken to intensive care
  • The length of stay in the ICU is more than 24 hours

Exclusion criteria

  • Patients under 18 years of age (2) Patients with hematological malignancies (3) The length of stay in the ICU is less than 24 hours.

Treatment and study plan

hemogram

Diagnostic Test

Sysmex XN-1000 hematological analyzer

Primary outcomes

  1. Hematological parameters in the prognosis of severe Covid-19 patients.

    Time frame: 2020-2021

    Hemogram values of the deceased and surviving patients participating in the study were compared.

Sponsors and collaborators

Lead sponsor

Hisar Intercontinental Hospital

Other

Registry information

Official study title

Department of Infectious Disease and Clinical Microbiology

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
Dec 14, 2022
Registry last updated
Dec 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.